Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.

BACKGROUND:Our objective is to compare the cost-utility of icotinib and gefitinib for the second-line treatment of advanced non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system. METHODS:Model technology was applied to assess the data of randomized clinical trials...

Full description

Bibliographic Details
Main Authors: Chunxiang Zhang, Hongmei Zhang, Jinning Shi, Dong Wang, Xiuwei Zhang, Jian Yang, Qizhi Zhai, Aixia Ma
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4807816?pdf=render

Similar Items

Similar Items